Stocks to Watch:

Ultragenyx CEO: Committed to helping patients pay for dru...

CNBC Videos
Ultragenyx is now up around 150 percent from its IPO price. Its CEO Dr. Emil Kakkis provides insight on the development of its drugs, and just how committed the company is to treating patients with the diseases its drugs treat.
View Comments (0)